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Because of limitations in the availability of data on primary care encounters, patient retention in human immuno-
deficiency virus (HIV) care is often estimated using laboratory measurement dates as proxies for clinical encoun-
ters, leading to possible outcome misclassification. This study included 83,041 HIV-infected adults from 14 clinical
cohorts in the North American AIDSCohort Collaboration on Research andDesign (NA-ACCORD) who had≥1 HIV
primary care encounters during 2000–2010, contributing 468,816 person-years of follow-up. Encounter-based re-
tention (REB) was defined as ≥2 encounters in a calendar year, ≥90 days apart. Laboratory-based retention (RLB)
was defined similarly, using the dates of CD4-positive cell counts or HIV-1 RNA measurements. Percentage of
agreement and the κ statistic were used to characterize agreement between RLB and REB. Logistic regression
with generalized estimating equations and stabilized inverse-probability-of-selection weights was used to elucidate
temporal trends and the discriminatory power of RLB as a predictor of REB, accounting for age, sex, race/ethnicity,
primary HIV risk factor, and cohort site as potential confounders. Both REB and RLB increased from 2000 to 2010
(from 67% to 78% and from 65% to 77%, respectively), thoughREB was higher thanRLB throughout (P < 0.01). RLB
agreed well with REB (80%–86% agreement; κ = 0.55–0.62, P < 0.01) and had a strong, imperfect ability to discrim-
inate between persons retained and not retained in care by REB (C statistic: C = 0.81, P < 0.05). As a proxy for REB,
RLB had a sensitivity and specificity of 84% and 77%, respectively, with misclassification error of 18%.
clinical encounters; clinical retention; HIV; laboratorymeasurements; measurement error; misclassification; proxies
Abbreviations: AIDS, acquired immunodeficiency syndrome; CI, confidence interval; HIV, human immunodeficiency virus; HIV-1,
HIV type 1; IDU, injection drug user; IPW, inverse-probability-of-selection weights; NA-ACCORD, North American AIDS Cohort
Collaboration on Research and Design; ROC, receiver operating characteristic; ROR, ratio of odds ratios.
Access to health care and its utilization for clinical moni-
toring in both healthy populations (for preventive care) and
unhealthy populations (for treatment) are vital components
of improving health outcomes. The reliable and ongoing use
of clinical services by patients as part of disease manage-
ment, or retention in care, is one such indicator of health-care
utilization. Epidemiologic tools have long been recognized as
being both available and useful for evaluation of evidence and
formulation of policies for health services (1). With health-
care reform (e.g., the Affordable Care Act) removing barriers
to linkage to care in the United States, an understanding of
how people seek health care and are retained in care is likely
to become increasingly valuable (2, 3). These questions speak
to identifying disparities in our health-care system and may
have a large impact on patient outcomes.
The study of contemporaneous human immunodeficiency
virus (HIV)/acquired immunodeficiency syndrome (AIDS) epi-
demiology in the United States has increasingly recognized
health-care retention as a key component in improving health
outcomes in individuals and decreasing transmission of HIV.
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It is a core indicator of quality care for HIV-infected persons
and a central feature of what has been termed the “HIV care
continuum” (4–7). In 2010, the National HIV/AIDS Strategy
advocated increasing the proportion of HIV-infected patients
in continuous care (8); and in 2012, the Institute of Medicine
outlined measures for assessing both the National HIV/AIDS
Strategy and benchmarks outlined in the Affordable Care Act
(9). More recently, the Department of Health and Human Ser-
vices adopted process indicators for HIV care (10), and the
President of the United States issued an Executive Order di-
recting the Office of National AIDS Policy to coordinate a
federal response to improve engagement across the HIV care
continuum (11, 12).
Amid heightened national emphasis on improving clinical
retention among persons with HIV infection, correctly quanti-
fying retention at the national, state, and local levels is essential
to accurately assess progress toward established benchmarks.
However, measures of retention in HIV care have varied de-
pending on data availability and the populations being studied,
with various demographic, clinical, and environmental charac-
teristics having been shown to influence care patterns over time
(13–16). Laboratory data have been widely used as surrogate
measures when data on primary care encounters are unavailable,
as is often the case in large surveillance studies using public
health laboratory data or cross-sectional population-based sur-
veys that sample across defined geographic areas (e.g., county
or state surveys). Such measures have been shown to be good
indicators of initial or overall access to clinical HIV care (17),
but there are no longitudinal data regarding concordance be-
tween measures of retention defined by HIV primary care en-
counters and those using surrogate laboratory measures (6, 9,
18, 19).
With widespread accessibility and use of laboratory mea-
sures adapted as indicators of ongoing clinical care, there is a
need to examine agreement across these measures, which are
based on varying data sources, so that policy-makers, re-
searchers, and other consumers of epidemiologic information
can better understand and interpolate the clinical care experi-
ence indicated by surrogate measures. Therefore, in this study
we quantified concordance between laboratory measures
(used as surrogates for direct measurement of clinical en-
counters) and clinical encounters in a North American con-
sortium of AIDS cohort studies.
METHODS
Population and study design
The North American AIDS Cohort Collaboration on Re-
search and Design (NA-ACCORD) is a large demographi-
cally, clinically, and geographically diverse collaboration
which has been collecting data from multi- and single-site in-
terval and clinical cohort studies in the United States and
Canada since 2006 (20). According to the Institute of Medi-
cine, the NA-ACCORD has demonstrated a constituent pa-
tient population that comprises a large proportion of and is
demographically similar to persons living with HIV/AIDS
in the United States, and it has been recognized as one of the
data systems adequate to assess and quantify quality-of-care
measures (including retention in clinical care) that will serve
as benchmarks for progress under the National HIV/AIDS
Strategy and the Affordable Care Act (9). Further details on
the NA-ACCORD collaboration have been published previ-
ously (20).
Clinical and demographic data from 25 cohort studies con-
tributing information to NA-ACCORD (including laboratory
test values and their collection dates, medical diagnoses and
dates, antiretroviral drugs used and prescription dates, clini-
cal encounter data, insurance status, and the first 3 digits of the
zip code of residence) are transmitted annually to a centrally
administered Data Management Core, where all contributed
data sets are harmonized. Data undergo quality control for
completeness and accuracy, including measures to reduce
the probability that an individual is concurrently participating
in more than 1 clinical cohort study. The activities of both the
NA-ACCORD centrally and each participating cohort study
have been reviewed and approved by their respective local in-
stitutional review boards.
Among clinical cohorts, only patients who made 2 or more
clinic visits within 12 months were enrolled in the NA-
ACCORD, limiting the NA-ACCORD clinical population
to patients established as being “in care.” For this analysis,
we examined adult participants who had 1 or more HIV pri-
mary care encounters between January 2000 and December
2010. Interval cohorts, with visits conducted outside of clin-
ical care activities (21), were excluded to allow an exclusive
focus on patterns of patient clinical care. The 14 included
clinical cohorts were comprised of patients from all 50 US
states; Washington, DC; Puerto Rico; and 9 of the 13 Cana-
dian provinces and territories.
Retention measures, factors associated with retention,
and follow-up
This study compared 2 strategies for quantifying clinical
retention. The first was encounter-based clinical retention
(REB), defined as the Institute of Medicine-based indicator:
≥2 HIV primary care encounters within each calendar year,
≥90 days apart (9). The second was laboratory-based reten-
tion (RLB), defined in the same fashion as REB but using dates
of CD4-positive T-lymphocyte (CD4+ cell) count or HIV
type 1 (HIV-1) RNA measurement rather than primary care
encounters as markers of care. Clinical systems submitting
data for these analyses, such as Kaiser Permanente Northern
California, the Veterans Aging Cohort Study, and others, ex-
tracted data on HIV primary care encounters directly from
electronic health records or from the billing system, both of
which create an encounter record only if the patient visit ac-
tually occurred; that is, these data reflect a visit only if the pa-
tient appeared for care, not just scheduled an appointment.
Because all cohort studies represented primary care settings,
not urgent care, these were adjudged to be true primary care en-
counters. Beyond HIV primary care encounters, those coded
as subspecialty care, emergency department, dental, mental
health, nursing, nutrition, orientation, pharmacy, social work/
case management, substance abuse, or other/unknown out-
patient encounters were excluded. Due to strong financial in-
centives, our clinical cohorts would require highly accurate
assessments of patient encounters for reimbursement purposes,
in either billing or electronic health records systems. Therefore,
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Table 1. Percentage of Person-Time Retained in Care for HIV-Positive Patients as Defined by Both Primary Care
Encounters and Laboratory Measures, According to Demographic, Clinical, and Geographic Characteristics,
NA-ACCORD, 2000–2010a







REB RLB κ %
Total 83,041 100 71 67 0.59 80
Age, years
<40 35,713 43 62 63 0.64 83
40–49 29,542 36 70 67 0.61 83
50–59 13,863 17 77 68 0.53 81
≥60 3,923 5 84 70 0.39 78
Sex
Male 67,951 82 71 66 0.57 80
Female 15,090 18 69 69 0.57 80
Race/ethnicity
Non-Hispanic white 33,207 40 72 69 0.56 82
Non-Hispanic black 34,175 41 69 62 0.60 82
Hispanic 9,510 11 72 73 0.64 86
Other/unknown 6,149 7 70 67 0.59 82
Primary HIV risk factor
Men who have sex with men 30,589 37 69 74 0.63 85
Injection drug user 14,329 17 69 58 0.58 80
Heterosexual contact 18,908 23 68 71 0.65 85
Other/unknown 19,215 23 76 59 0.49 77
CD4-positive T-lymphocyte count, cells/mm3 d
<200 19,322 29 70 69 0.64 85
200–349 14,718 22 73 74 0.63 86
350–499 12,940 20 74 75 0.61 85
≥500 19,061 29 75 76 0.59 85
HIV-1 RNA level, copies/mLd
<200 16,972 27 81 83 0.52 86
≥200 45,205 73 69 68 0.63 84
Receipt of ART for ≥6 months/yeare
No ART 46,449 56 50 42 0.57 79
ART 36,592 44 83 82 0.46 84
Country of care
United States 79,236 95 70 66 0.58 82
Canada 3,805 5 74 75 0.66 87
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; HIV-1, HIV type 1; NA-ACCORD,
North American AIDS Cohort Collaboration on Research and Design.
a Encounter-based retention (REB) was defined as ≥2 primary care encounters in a calendar year, ≥90 days apart.
Laboratory-based retention (RLB) was defined similarly, using the dates of CD4-positive cell counts or HIV-1 RNA
measurements.
b Percentages may not sum to 100 because of rounding.
c The percentage of person-time retained in care during the study according to the encounter-basedmeasure (REB)
(i.e., the percentage of years spent “in care” between cohort entry and the final encounter) differed from the percentage
of person-time retained according to the laboratory-based measure (RLB) within every stratum (χ
2 test: P < 0.01).
d Data on CD4-positive cell count (n = 66,041) and HIV-1 RNA level (n = 62,177) at cohort entry were not available
for all participants.
e Receipt of ART (≥3 agents from ≥2 classes or a triple nucleoside/nucleotide reverse transcriptase inhibitor
regimen containing abacavir or tenofovir) during the year of cohort entry.
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any error in capturing the dates of patient HIV primary care
encounters—very basic functions in these systems—should
have been negligible and more likely random than systematic
in nature, though no additional validation was performed.
Therefore, no bias should have been introduced by their
use as described in this analysis. Inpatient data were also
excluded.
Data from individuals were used to create 1 observation
per year between the year of the person’s entry into the cohort
and the year of his/her final encounter or laboratory measure-
ment prior to the end of 2010. This single annual observation
carried a summaryof the individual’s retention status, depend-
ing on whether his/her data for that year met criteria for REB
or RLB (see Web Appendix 1 and Web Figure 1, available at
http://aje.oxfordjournals.org/). The initial year of care in the
cohort was excluded if the patient entered in the final quarter
of a calendar year (and was thus ineligible to be “retained”
in his/her year of entry into care). The year of death was ex-
cluded for patients who died before the end of the study (due
to individuals not being uniformly at risk for the outcome in
the year of death, dependent on the timing of their death dur-
ing the calendar year). Follow-up time ranged between a min-
imum of 1 year and a maximum of 11 years, and individuals
could contribute multiple observations over the study period.
Participant age (categorized as <40 years, 40–49 years,
50–59 years, or ≥60 years), sex, self-characterized race/
ethnicity (categorized as white, black, Hispanic, or other/
unknown), self-characterized primary risk factor for HIVacqui-
sition (categorized as men who have sex with men, injection
drug user (IDU), heterosexual contact, or other/unknown), re-
ceipt of antiretroviral therapy for ≥6 months in a year (≥3 an-
tiretroviral agents from ≥2 classes, or a triple nucleoside/
nucleotide reverse transcriptase inhibitor regimen containing
abacavir or tenofovir), CD4+ cell count (categorized as <200,
200–349, 350–499, or ≥500 cells/mm3), HIV-1 RNA level
(categorized as <200 or ≥200 copies/mL), and site of clinical
care were included in descriptive analyses as factors by which
the agreement between REB and RLB may have differed. Re-
ceipt of antiretroviral therapy, CD4+ cell count, and HIV-1
RNA level were excluded from regression analyses because
of their potential to induce bias as time-dependent confound-
ers of the relationship between RLB and REB. CD4+ cell
counts were the first values measured in the calendar year
of cohort entry, and HIV-1 RNA levels were the last values
measured; the choice of relative timing for these measures
was related to widely used indicators of clinical care (9).
All factors were time-varying except sex, race/ethnicity, and
primary HIV risk factor.
Statistical models and methods
Percentage of agreement, discordance (percentage of neg-
ative agreement), sensitivity, specificity, and the kappa statis-
tic (κ) were all used to quantify agreement between REB and
RLBacrossandwithindemographic andclinical characteristics
(22). Differences between REB and RLB within strata of base-
line characteristics were detected by χ2 test. Weighted logistic
regression using a generalized estimating equation was used
to assess temporal trends and construct receiver operating
characteristic (ROC) curves with their respective C statistics
to assess the discriminatory power of RLB as a predictor of
REB (23, 24). A Toeplitz correlation structure based on the
mean values of the unstructured covariance for repeated out-
comes within individuals was used in the generalized esti-
mating equation regression (25, 26).
Construction of stabilized inverse probability weights
Inverse-probability-of-selection weights (IPW) are an in-
creasingly popular strategy for addressing the problem of
confounding. By reweighting (or standardizing) populations
with respect to the exposure conditional on measured poten-
tial confounders, we can eliminate the exposure-confounder
link when estimating the effect or association of the exposure
with the outcome (27). In this analysis, we used these tech-
niques to determine the marginal relationship between REB
and RLB while accounting for the potential confounders base-
line age, sex, race/ethnicity, primary HIV risk factor, and
cohort site in the regression model (28). These were time-
fixed confounders, so we used single weights across all time
points for an individual. The weights were also stabilized
and truncated at the 5th and 95th percentiles to improve
balance (29).
The weights themselves were constructed using regression
to estimate the probability of exposure, conditioning on the
appropriate confounding factors. Because the exposure of in-
terest was RLB, a dichotomous variable, a logistic regression
model was used to create the IPW. Additional details on
model diagnostics used in the selection and construction of
the Toeplitz correlation structure for the regression with a
generalized estimating equation (Web Appendix 2, Web Fig-
ures 2 and 3,Web Table 1) and the distribution of untruncated





























Figure 1. Temporal trends in encounter- and laboratory-based mea-
sures of retention in care (REB and RLB, respectively) and agree-
ment between measures (% agreement and κ coefficient) in the
North American AIDS Cohort Collaboration on Research and Design
(NA-ACCORD), 2000–2010. Dashed-and-dotted lines across REB
and RLB percentages are locally weight scatterplot smoothing
(LOESS) curves for trend. κ estimates (diamonds) are plotted with
95% confidence intervals (bars).
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and truncated IPW accounting for site alone and for all avail-
able confounders (Web Appendix 3, Web Figure 4) are given
in the Web appendices. All analyses were performed using
R, version 3.0.3 (R Foundation for Statistical Computing,
Vienna, Austria) (www.r-project.org).
RESULTS
Among 83,041 adults included in the study population, the
median amount of time contributed was 4 years (interquartile
range, 2–6 years), with a total contribution of 468,816 person-
years. There were significant differences in REB versus RLB
across all patient demographic and clinical factors (Table 1).
The person-time retained ranged between 60% and 80% for
both REB and RLB for most characteristics but was lower
among persons with a primary HIV risk factor of IDU and
those not receiving antiretroviral therapy for ≥6 months per
year. Despite these differences, according to accepted epide-
miologic measures, there was good agreement between REB
and RLB within all demographic and clinical strata (77%–
87% agreement; κ = 0.39–0.66, all P’s < 0.01) (Table 1).
There were increases in retention throughout the study
period according to both definitions, though retention was
higher when it was measured byREB throughout (P < 0.01 for
trend; Figure 1). For REB, the proportion of patients retained
increased from 67% (20,591/30,741) in 2000 to 78% (26,701/
34,205) in 2010. Similarly, for RLB, 65% (20,020/30,741)
and 77% (26,357/34,205) of patients were retained in 2000
and 2010, respectively (Figure 1). There was fair agreement
between REB and RLB over time (80%–86% agreement; κ =
0.55–0.62, P < 0.01) (Figure 1).
Regression models utilizing a generalized estimating equa-
tion, with and without stabilized IPW to account for potential
variations in practice across clinical sites (REB ranged from
62% to 85% across sites and RLB from 51% to 79%) and dif-
ferences across age, sex, race/ethnicity, and HIV risk catego-
ries, were used to construct ROC curves. Using the area under
the ROC curve for the weighted model, RLB had a strong but
imperfect ability to discriminate between persons retained in
care and those not retained by REB (C = 0.805, P < 0.05) (Fig-
ure 2A). Using the area under the ROC curve for the robust
adjustedmodel (incorporating IPW to adjust for site, age, sex,
race/ethnicity, and primary HIV risk factor), the discrimina-
tion of RLB was improved slightly over that of the unweighted
model (C = 0.868, P < 0.05) (Figure 2B). Using predicted
probabilities of REB from the regression models plotted as
thresholds along the ROC curves, the sensitivities and spec-
ificities of RLB as a proxy for REB were maximized at a reten-
tion probability of 30% in the marginal weighted model and
at retention probabilities of 60% to 80% in the adjusted
weighted model, which was in the range of observed reten-
tion levels over the study period (Figure 2A and 2B). Using
weighted model estimates, the sensitivity and specificity of
RLB as a proxy for REB in the pseudopopulation were 84%
and 77%, respectively, which resulted in a discordance of
18% (Table 2). Results were similar when using predicted
probabilities from the weighted regression model and shorter
intervals during the study period (2000–2003, 2004–2007,
and 2008–2010), though discordance according to RLB was
slightly higher in earlier periods (18% and 19%, respectively)
than in the most recent period (16%). Exclusion of the largest
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Figure 2. Receiver operating characteristic (ROC) curves quantifying the discrimination of an encounter-based measure of retention of human
immunodeficiency virus (HIV)-positive patients in care (REB) by a laboratory-basedmeasure of retention in care (RLB), North American AIDSCohort
Collaboration on Research and Design (NA-ACCORD), 2000–2010. The curves were derived from regression models with generalized estimating
equations and inverse-probability-of-selection weights (IPW). A) ROC curve with IPW based on site, age, sex, race/ethnicity, and primary HIV risk
factor. B) ROC curve derived from a model with robust adjustment for clinic site with IPW. Predicted probabilities of retention by REB are thresholds
on the ROC curves.
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accessing care, resulted in RLB’s being closer to REB through-
out the study period, with only a slight elevation in the percent-
age of agreement and κ values (percent agreement ≤ 87% and
κ≤ 0.67; data not shown). In addition, the overall misclassifi-
cation error (discordance) dropped slightly from 18% to 16%.
Application of the same approaches within subpopulations
of special concern (e.g., younger, minority, female, and IDU
patients) revealed similar patterns of improving retention
over time. However, in weighted regression analysis with
factor-by-RLB joint-effect interactions, also including main
effects, agreement between REB and RLB was lower among
persons over age 50 years versus persons aged≤50years (ratio
of odds ratios (ROR) = 0.71, 95% confidence interval (CI):
0.67, 0.74) and IDU patients versus non-IDU patients (ROR =
0.91, 95% CI: 0.86, 0.96) and was higher among females ver-
sus males (ROR = 1.12, 95%CI: 1.06, 1.18) and black patients
versus nonblack patients (ROR = 1.05, 95% CI: 1.01, 1.10)
(Figure 3).
DISCUSSION
The accurate measurement of retention in care has implica-
tions for the epidemiology and management of HIV infection
in the United States and Canada, as well as the design, imple-
mentation, and evaluation of prevention and treatment strate-
gies for HIV and other chronic diseases (8). It is also clear that
measuring clinical retention accurately per policy guidelines
and refining targets for improvement are consistent with the
recent emphasis on a “test and treat strategy” to rapidly diag-
nose HIV-infected persons and engage them in continuous
care, which has been theorized to “bend the incidence curve”
of HIV in the United States and Canada downward (30, 31).
Therefore, in this study we sought to leverage longitudinal
clinical data available within a large, demographically and
geographically diverse collaborative consortium of cohort
studies to elucidate the critical and underexplored issue of mis-
classification when using laboratory proxies for clinical en-
counters in describing the epidemiology of clinical retention.
Even in a clinically engaged population who have success-
fully linked to health care, using laboratory measures as prox-
ies for clinical encounters does not provide a complete picture
of engagement in care as recommended by recently adopted
indicators (9, 10, 32). The potential for misclassification of
an encounter-based retention outcome based on laboratory-
based retention measures is small but nontrivial, ranging
from 15% discordance to 20% discordance. Moreover, we
Table 2. Agreement Between Encounter-Based Measures (REB) and Laboratory-Based Measures (RLB) of















Weighted data using IPW 468,816 17 86 79 0.63
Regression model with IPW 468,816 0.87 18 84 77 0.58
Abbreviations: HIV, human immunodeficiency virus; IPW, inverse-probability-of-selection weights; NA-ACCORD,
North American AIDS Cohort Collaboration on Research and Design.
a Estimated from a model using stabilized IPW constructed using clinic site, age, sex, race/ethnicity, and primary
HIV risk factor.




IDU HIV Risk 0.91 (0.86,  0.96)
1.05 (1.01,  1.10)
1.12 (1.06,  1.18)
0.71 (0.67,  0.74)
0.6 0.7 0.8 0.9 1 1.1 1.2
GEE Model ROR (95% CI)
Figure 3. Ratios of odds ratios (RORs) and 95% confidence intervals (CIs) for the probability of retaining human immunodeficiency virus (HIV)-
positive patients in care as assessed by an encounter-based measure (REB), conditional on retention assessed by a laboratory-based measure
(RLB), among subpopulations of concern ( joint-effects interactions), North American AIDS Cohort Collaboration on Research and Design
(NA-ACCORD), 2000–2010. Reference groups: for age, ≤50 years; for sex, male; for black race, nonblack race; for injection drug use (IDU) as
the primary HIV risk factor, a non-IDU primary HIV risk factor. GEE, generalized estimating equations.
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identified significant (although modest in magnitude) inter-
actions between the level of agreement in these measures
and membership in subpopulations of special concern in
the HIV epidemic; this should alert epidemiologists to the
possibility of differential misclassification.
There are many reasons REB may not agree perfectly with
RLB. For example, in one participating cohort study, initial
laboratory panels were ordered at enrollment by medical
care management personnel, prior to the patient’s first clini-
cal encounter. In other instances, clinics facilitated laboratory
monitoring at regular intervals under standing orders from
clinicians, without the requirement of a direct clinical en-
counter. Alternatively, patients may access laboratory testing
at a facility that does not require clinical orders (though this
may be relatively rare). In any of these cases, patients may
meet the definition of retention by RLB even if not by REB.
The opposite may hold for patients receiving clinical care
without laboratory monitoring at regular intervals.
Though the frequency of laboratory monitoring may be of
great concern to a clinician or epidemiologist depending on
the needs of the clinic population served, it is not equivalent
to the frequency of clinic attendance, even at a less granular
level (e.g., an annually assessed retention indicator), and may
not serve the same policy or monitoring purposes despite its
utility otherwise. This is denoted in the language of the Insti-
tute of Medicine report, which refers to laboratory measures
as “proxies” for encounter-based measures (9, 17). The use of
CD4+ cell counts and HIV-1 RNA measurements to denote
retention may also be of concern, since monitoring frequency
guidelines or state/local reporting practices for HIV-related
laboratory measures may change in different populations (19,
33). In particular, as guidelines continue to decrease the rec-
ommended frequency of laboratory monitoring among stable
patients on antiretroviral therapy, the degree towhich laboratory-
based measures will underestimate the population of retained
patients will increase. Thus, it is not obvious that one method-
ology is superior to the other; qualitymeasures of timely labora-
torymeasurement andof timelyencountersmayboth havemerit.
Additionally, we are not asserting that assessing retention
using laboratory proxies is a worthless endeavor (the perfect
ought not be the enemy of the good). Neither are encounter-
based retention measures the “gold standard” for measuring
the clinical experience of patients (the engagement of patients
in their own care and resulting improved HIV disease progres-
sion may well be a mixture of interactions with clinicians and
receipt of ancillary services); there could also be limitations in
complete capture of all encounter data when formulating REB
measures. However, when policies or strategies are structured
around indicators defined using a particular measure, monitor-
ing the effects of those policies with fidelity to their design may
be limited by reliance on imperfect proxies. The use of labora-
torymeasures as surrogates for primary care encounters by pub-
lic health agencies is, after all, an exercise in maximizing the
utility of readily available data, and while statistically different
they are within reasonable range of each other. Researchers and
policy-minded professionals interested in assessing population-
level changes in health-care service indicators using these data
must be aware of the constraints their estimates face.
As it stands, not all CD4+ cell counts or HIV-1 RNAmea-
surements are uniformly reported across jurisdictions to the
National HIV Surveillance System; currently, mandatory re-
porting of all values is the legal standard in 42 of the 50 US
states and Washington, DC, although, as of 2014, only 18 ju-
risdictions (representing 52% of adults diagnosed with HIV
in the United States) were considered to have “complete” re-
porting sufficient to include in annual surveillance estimates
(34). The Centers for Disease Control and Prevention has im-
plemented the Medical Monitoring Project, which collects
both clinical encounter and HIV laboratory information to
supplement the National HIV Surveillance System, but the
Medical Monitoring Project is limited by its cross-sectional
design (35). When examining retention at the population level,
then, there may be few options for researchers and policy an-
alysts other than employing proxy measures, though these
data may be incomplete indicators of REB. Again, a discord-
ance of 15%–20% between REB and RLB is plausible based
on the results from our large cohort. Though evaluation of
possible differences in agreement between REB and RLB by
state of patient residence was outside the scope of the current
analysis, it is also possible that incomplete data due to differ-
ences in reporting practices could be ameliorated and reten-
tion itself improved by the implementation of secure health
information exchanges or other emerging data-sharing solu-
tions (36, 37). Such exchanges, resulting in unified health
records, could potentially greatly improve surveillance activ-
ities for health-care service outcomes, even beyond HIV.
That being said, it is important to recognize that the results
of this analysis do not show a large divergence between REB
and RLB. For monitoring purposes, it may be the case that use
of one versus the othermay result in different judgments about
whether a particular benchmark for clinical retention has
been met, but the size of the misclassification error compar-
ing one with the other is low enough that the distinction may
not be as important above a particularly high benchmark. For
example, the National HIV/AIDS Strategy establishes a goal
to “increase the proportion of Ryan White HIV/AIDS Pro-
gram clients who are in continuous care . . . from 73% to
80%” (8, p. 21). While previous years showed greater dis-
cordance, results from 2010, with 77% of patients success-
fully retained according to RLB, may not be meaningfully
different for either policy or clinical purposes from a popula-
tion that is 78% retained byREB (8).Whatever the difference in
different populations, though, it remains important to quantify
it and to speak clearly and openly about the fact that these two
measures are not completely interchangeable and, in the future,
may or may not become even more divergent.
There were limitations in this analysis due to characteris-
tics of the study population and the statistical traits of some
measures of agreement. Because of the high prevalence of re-
tention in this population, the κ statistic in particular may
have returned artificially low estimates of agreement; this
may also occur when the prevalence of the outcome is very
low (22). However, multiple measures of agreement and pre-
dictive discrimination were used to achieve a more complete
picture of the relationship between REB and RLB over time in
this population. Another potential limitation of this analysis
is that results obtained using the NA-ACCORD patient pop-
ulation may not fully represent the continuum of care ex-
perienced by all patients, particularly if they access clinical
care outside the network of sites in NA-ACCORD, though
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NA-ACCORD participant sites comprise a wide array of clin-
ical settings across the United States and Canada—county
hospitals, private practices, health maintenance organizations,
Veterans Affairs facilities, etc. Further, our results appeared
sensitive to the exclusion of our largest cohort, though levels
of retention and intermeasure agreement were quite similar to
those in the overall cohort, using weighted analyses. This may
suggest the influence of individual cohort characteristics on
agreement between measures, though this is expected if clin-
ical sites have very different models of care. Because all data
in NA-ACCORD are anonymized before being harmonized at
the central DataManagement Core, there is noway of tracking
the movement of individuals between cohort sites (though the
large geographic dispersion of sites makes it likely that indi-
viduals are not simultaneously accessing care at disparate
locations); there may be misclassification error in the outcome
if patients leave care at a member site and access care through
a local public health department, private physician’s office,
unaffiliated local hospital, or other venue, because they may
appear to be experiencing suboptimal retention during that pe-
riod even though they are not. However, this would be a short-
coming in any setting where there is not a comprehensive,
nationally linked medical records or claims database. Despite
these potential limitations, NA-ACCORD has a very large
sample size that is demographically representative of persons
livingwith HIV/AIDS in theUnited States, represents persons
living in geographically diverse regions of the United States
and Canada, and has been formally endorsed as an ideal
data source with which to assess progress under the National
HIV/AIDS Strategy, which is an exercise related to just the
sorts of issues addressed above (9, 38).
In summary, this analysis showed that clinical retention by
both REB and RLB improved over time and that REB and RLB
were strongly correlated. However, our findings suggest that
RLB was an imperfect surrogate for REB, and we were able to
quantify the level of imperfection. The discordance between
encounter retention status and widely used laboratory proxies
provides further motivation for the development of novel
health information-sharing strategies and structures to facili-
tate the most accurate assessment of HIV clinical retention
possible.
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